Inventiva: acclaimed for issuance of royalty certificates

(CercleFinance.com) - Inventiva climbs nearly 8% following the announcement of the issuance of royalty certificates subscribed by Samsara BioCapital, BVF Partners, NEA, Sofinnova and Yiheng, for an approximate amount of 20.
1 million euros.

These certificates entitle their holders to receive royalties of 3% on future net sales of lanifibranor in the United States, the European Union and the United Kingdom, over a period of 14 years.

The biopharmaceutical company intends to use approximately 95% of the net proceeds from the transaction to continue the Phase III NATiV3 trial with lanifibranor in MASH/NASH (NATiV3), and the remainder for general corporate purposes.

Copyright (c) 2024 CercleFinance.com. All rights reserved.